Silo Pharma, Inc. (SILO) Research

Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.

Market snapshot

Symbol
SILO
Price
$6.12
Day change
+5.34%
Market cap
$5.5M
P/E ratio
-1.15x
52-week range
3.315-15.15
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Recent news

  • Silo Pharma Rallies After Securing Key Patent Allowance

    Silo said the European Patent Office issued a Rule 71(3) communication indicating its intent to grant a patent for the application, which the company has an exclusive license from Columbia University.

  • Stock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline—UnitedHealth, Silo Pharma, Phillips 66 In Focus

    Meanwhile, Iran has submitted a 10-point response to the U.S. peace proposals, which a U.S. official described as "maximalist", citing the Iranian state news agency IRNA.

  • Silo Pharma (SILO) Stock Soars 47% After European Patent Win: What You Should Know

    Silo Pharma stock jumps after-hours after European patent allowance for PTSD prevention therapy targeting 5-HT4 pathway.

Peer companies

  • Biodexa Pharmaceuticals Plc (BDRX)
  • Can-Fite BioPharma Ltd. (CANF)
  • Clearmind Medicine Inc. (CMND)
  • CNS Pharmaceuticals, Inc. (CNSP)
  • GRI Bio, Inc. (GRI)
  • InMed Pharmaceuticals Inc. (INM)
  • Jaguar Health, Inc. (JAGX)
  • Kazia Therapeutics Limited (KZIA)

Recent insider activity

  • Weisblum Eric — P-Purchase (2500 shares) on 2025-12-15
  • Weisblum Eric — P-Purchase (2500 shares) on 2025-12-15
  • Weisblum Eric — P-Purchase (1000 shares) on 2025-11-21
  • Weisblum Eric — P-Purchase (1000 shares) on 2025-11-20
  • Weisblum Eric — P-Purchase (4500 shares) on 2025-11-19

Open Silo Pharma, Inc. (SILO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.